17-(Allylamino) Geldanamycin is primarily utilized in biomedical research due to its role as a heat shock protein 90 (Hsp90) inhibitor. This compound is instrumental in studying the mechanisms of protein folding and degradation, as Hsp90 is a crucial chaperone protein involved in stabilizing and activating a wide range of client proteins, many of which are implicated in cancer and other diseases. By inhibiting Hsp90, it helps researchers understand the pathways that lead to the degradation of oncogenic proteins, making it a valuable tool in the development of targeted cancer therapies. Additionally, it is used in preclinical studies to explore its potential efficacy in treating neurodegenerative diseases, where protein misfolding and aggregation are key pathological features. Its application extends to investigating cellular stress responses and the role of Hsp90 in maintaining cellular homeostasis under various conditions.